Core D: BiostatisticsThe objectives of the Biostatistics Core are to provide collaborative support for study design, data analysis,and dissemination of results for all SPORE projects, in addition to developing novel statistical methods tohandle unique analysis problems, as needed.Statistical and methodological support is critical to ensure the quality of the design, conduct, analysis, andreporting of scientific trials and studies. With related experimental design and conceptual components, someof the quality control and analytic issues will be shared among the projects. By using the shared resource ofthe Biostatistics Core, all SPORE projects will benefit from the experience gained in each project. TheBiostatistics Core investigators have extensive and complementary experience in quantitative methods forbiomedical applications, including both clinical and basic science studies. They are committed to taking adirect interest in the substantive issues being investigated, to participating in regular project and programmeetings, and to providing rigorous and innovative input on all quantitative matters arising in the projects.The 5 Specific Aims of the Biostatistics Core are to:1. Provide detailed consultation for the development of all study protocols, including clinical trials. Thisincludes study design, defining outcome variables and important covariates, developing appropriatemeasures and methods to obtain the relevant data necessary to properly answer the study questions,identifying appropriate statistical methods for analysis, and performing power and sample sizecalculations.2. Provide biostatistical support during the conduct of the studies. This includes a synergisticrelationship with the Clinical Trials Core to provide quality control and routine report generation aswell as to assist in making any decisions related to protocol changes or revisions.3. Collaborate in the interim and final statistical analyses of the study data. This includes identifyingappropriate statistical methodology, statistical programming, data analysis, assisting with theinterpretation of the results of analyses, and producing final reports and graphical displays suitablefor presentation and publication.4. Develop novel statistical methods to handle unique analysis problems, as needed.5. Collaborate in the preparation of manuscripts and presentations of the results of the studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA130805-01A1
Application #
7507438
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-01
Project End
2013-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$121,471
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Runckel, Kyle; Barth, Matthew J; Mavis, Cory et al. (2018) The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv 2:3516-3525
Akhenblit, Paul J; Hanke, Neale T; Gill, Alexander et al. (2016) Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. Mol Imaging 15:
Havas, Aaron P; Rodrigues, Kameron B; Bhakta, Anvi et al. (2016) Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biol Ther 17:1240-1252
Holkova, Beata; Kmieciak, Maciej; Bose, Prithviraj et al. (2016) Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma 57:635-43
Nedelkovska, Hristina; Rosenberg, Alexander F; Hilchey, Shannon P et al. (2016) Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One 11:e0155347
Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej et al. (2016) A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22:1067-75
Zhou, L; Zhang, Y; Chen, S et al. (2015) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:807-18
Jaramillo, Melba C; Briehl, Margaret M; Batinic-Haberle, Ines et al. (2015) Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med 83:89-100
Chen, Liu Qi; Howison, Christine M; Spier, Catherine et al. (2015) Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk Lymphoma 56:1432-9
Kiebala, Michelle; Skalska, Jolanta; Casulo, Carla et al. (2015) Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol 43:89-99

Showing the most recent 10 out of 115 publications